Applied Therapeutics Securities Settlement
Did you buy or otherwise acquire Applied Therapeutics, Inc. (NASDAQ: APLT) common stock on a U.S. exchange between January 3 2024 and December 2 2024? You could receive money—and potential warrant proceeds—from a proposed $15 million cash settlement plus warrants. File your claim online or download the claim form below before the April 8 2026 deadline.
Download Claim Form (PDF)Who Is Included?
All persons or entities that purchased or otherwise acquired Applied Therapeutics publicly-traded common stock on a U.S.-based exchange between January 3 2024 and December 2 2024, inclusive, and are not otherwise excluded, are part of the Settlement Class.
What the Settlement Provides
- Cash Fund: $15,000,000.
- Warrants: Rights to purchase up to 1,000,000 APLT shares at $0.48 per share. Any net proceeds realized for the class will be added to the cash fund.
- The Net Settlement Fund will be distributed to eligible investors under a Court-approved Plan of Allocation.
Important Deadlines
- Claim Filing Deadline: April 8 2026
- Exclusion (Opt-Out) Deadline: February 26 2026
- Objection Deadline: February 26 2026
- Final Approval Hearing: March 19 2026
Your Legal Rights & Options
- Submit a Claim: Receive a payment. Must file by April 8 2026.
- Exclude Yourself: Get no payment but keep your right to sue the defendants on your own. Request must be received by February 26 2026.
- Object: Write to the Court about why you do not like the settlement. Must be received by February 26 2026.
- Go to the Hearing: Ask to speak in Court about the settlement’s fairness on March 19 2026.
- Do Nothing: Get no payment and forfeit the right to sue later.
Background of the Case
Investors allege Applied Therapeutics and certain officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by issuing materially false or misleading statements about:
- The viability of its new drug application for govorestat to treat Classic Galactosemia.
- Interactions and compliance with the U.S. Food and Drug Administration.
- Dosing errors and deleted source data in the pivotal pediatric study.
Defendants deny all wrongdoing. The parties reached this settlement to avoid the costs and risks of continued litigation. The Court has not decided in favor of either side.
Need Help?
For more information, visit the official settlement site, review the full notice, or contact the Claims Administrator:
- Settlement Website
- Phone: (833) 703-4229
- Email: Info@APLTSecuritiesSettlement.com
- Mail: Applied Therapeutics Securities Settlement, c/o Claims Administrator, 1650 Arch Street, Suite 2210, Philadelphia, PA 19103
FAQ
What is the Applied Therapeutics Securities Settlement about?
The lawsuit alleges the company misled investors about the integrity of clinical-trial data and its FDA new drug application for govorestat. The settlement resolves these claims in exchange for $15 million in cash plus warrants.
How do I submit a claim?
You can file online at the settlement website or mail the completed Proof of Claim and Release form so it is postmarked by April 8 2026.
What happens if I do nothing?
You will remain in the class, lose the right to sue the defendants about the same issues, and receive no payment.
Who represents the class?
Lead Counsel is Wolf Popper LLP. You may also hire your own lawyer at your own expense.
When will I get paid?
Payments are made after the Court grants final approval and any appeals are resolved. Please be patient.